Worried About Novavax? Here's What You Can Do to Minimize Your Risk
COVID-19 vaccine maker Novavax (NASDAQ: NVAX) has been a volatile stock to own over the past year. Although its shares are up over 60% during the past 12 months (beating the S&P 500 and its 36% gains), it is also trading at less than half of its 52-week high of $331.68 that it hit earlier this year.
There's a lot riding on the success of its COVID-19 vaccine candidate. If it flops and the company doesn't obtain Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in the coming months, shares of the healthcare company could nosedive even further.
Image source: Getty Images.
Source Fool.com
